Table 4.
Overall responses to PG-11047 combination therapies.
| SD | PR | median duration of SD (range) (d) | |
|---|---|---|---|
| gemcitabine | 57.1% (4/7) | 0 | ND (52 – 195) |
| docetaxel | 50.0% (4/8) | 0 | 93 (29 – 110) |
| bevacizumab | 40.0%(10/25) | 12.0% (3/25) | 145 (42 – 239) |
| erlotinib | 33.3% (8/24) | 0 | 116 (57 – 173) |
| cisplatin | 54.1% (20/37)* | 0 | 141(40 – 200) |
| (leucovorin) 5-FU | 71.4 (15/21) | 0 | 119 (53 – 132) |
| sunitinib | 0% | 0 | ND |
*
4 of these 20 patients had unconfirmed PRs; ND, not determinable due to sample size; SD, Stable Disease; PR, Partial Response